A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies

Authors:

Abstract
To determine the therapeutic efficacy (13-week and 26-week CNS progression-free survival [PFS], response rate, and overall survival) and safety of in

This publication has 18 references indexed in Scilit: